Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8880908 | 0.94 | ALDH1A1 (0.38) | ALDH1A1KDM4ESLC29A1PAOXDRD2 | |
| SCHEMBL6945807 | 0.89 | ALDH1A1 (0.38) | ALDH1A1KDM4ESLC29A1PAOXDRD2 | |
| SCHEMBL10924619 | 0.87 | ALDH1A1 (0.39) | ALDH1A1KDM4ESLC29A1DRD2HRH3 | |
| SCHEMBL11575418 | 0.87 | — | — | |
| SCHEMBL3451890 | 0.85 | HSD11B1 (0.42) | ALDH1A1KDM4ESLC29A1PAOXDRD2 | |
| SCHEMBL6042277 | 0.85 | DRD2 (0.40) | ALDH1A1KDM4ESLC29A1DRD2HSD11B1 | |
| SCHEMBL11574905 | 0.84 | — | — | |
| SCHEMBL10930283 | 0.82 | HSD11B1 (0.42) | ALDH1A1KDM4ESLC29A1HSD11B1HRH3 | |
| SCHEMBL10927336 | 0.82 | HRH3 (0.46) | ALDH1A1PAOXHRH3GNAI3GNAO1 | |
| SCHEMBL11570576 | 0.82 | HRH3 (0.46) | ALDH1A1PAOXHRH3GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | ALDH1A1 1039/4885KDM4E 1951/4885SLC29A1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.